Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) Invested Capital: 2013-2025

Historic Invested Capital for Ocular Therapeutix (OCUL) over the last 12 years, with Sep 2025 value amounting to $258.2 million.

  • Ocular Therapeutix's Invested Capital fell 26.64% to $258.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $258.2 million, marking a year-over-year decrease of 26.64%. This contributed to the annual value of $315.3 million for FY2024, which is 145.15% up from last year.
  • Per Ocular Therapeutix's latest filing, its Invested Capital stood at $258.2 million for Q3 2025, which was down 15.59% from $305.9 million recorded in Q2 2025.
  • Ocular Therapeutix's 5-year Invested Capital high stood at $408.0 million for Q1 2024, and its period low was $3.1 million during Q2 2023.
  • Moreover, its 3-year median value for Invested Capital was $265.9 million (2025), whereas its average is $223.4 million.
  • In the last 5 years, Ocular Therapeutix's Invested Capital slumped by 95.31% in 2023 and then skyrocketed by 12,135.02% in 2024.
  • Over the past 5 years, Ocular Therapeutix's Invested Capital (Quarterly) stood at $120.9 million in 2021, then slumped by 39.72% to $72.9 million in 2022, then skyrocketed by 76.49% to $128.6 million in 2023, then surged by 145.15% to $315.3 million in 2024, then declined by 26.64% to $258.2 million in 2025.
  • Its Invested Capital stands at $258.2 million for Q3 2025, versus $305.9 million for Q2 2025 and $265.9 million for Q1 2025.